Pooled 48-week results from two Phase II studies show sustained antiviral responses and a favorable safety profile of AHB-137 in HBeAg-negative chronic hepatitis B patients on NA therapy. SAN FRANCISCO, Nov. 8, 2025 /PRNewswire/ -- AusperBio Therapeutics, Inc. and Ausper Biopharma Co.,...
Hence then, the article about ausperbio announces late breaking 48 week phase ii data of ahb 137 in chronic hepatitis b at aasld 2025 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( AusperBio Announces Late-Breaking 48-Week Phase II Data of AHB-137 in Chronic Hepatitis B at AASLD 2025 )
Also on site :
- Katie Couric Shares Photo From Hospital Bed With Important PSA: 'Wish Me Luck'
- Indie Rock Band Announces Summer Tour Dates—Including First-Ever Stop
- Zelensky eliminating opponents before elections – opposition leader